(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.10%) $2 349.60
(-0.07%) $27.52
(0.42%) $924.40
(0.36%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
-0.69% KRW 5 750.00
Live Chart Being Loaded With Signals
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions...
Stats | |
---|---|
Volumen de hoy | 130 264 |
Volumen promedio | 696 933 |
Capitalización de mercado | 345.02B |
EPS | KRW0 ( 2024-02-12 ) |
Próxima fecha de ganancias | ( KRW0 ) 2024-05-12 |
Last Dividend | KRW0 ( N/A ) |
Next Dividend | KRW0 ( N/A ) |
P/E | 0 |
ATR14 | KRW10.68 (0.19%) |
Volumen Correlación
Pharmicell Co., Ltd. Correlación
10 Correlaciones Más Positivas |
---|
10 Correlaciones Más Negativas |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Pharmicell Co., Ltd. Correlación - Moneda/Commodity
Pharmicell Co., Ltd. Finanzas
Annual | 2023 |
Ingresos: | KRW56.23B |
Beneficio Bruto: | KRW14.96B (26.60 %) |
EPS: | KRW59.63 |
FY | 2023 |
Ingresos: | KRW56.23B |
Beneficio Bruto: | KRW14.96B (26.60 %) |
EPS: | KRW59.63 |
FY | 2022 |
Ingresos: | KRW60.18B |
Beneficio Bruto: | KRW23.82B (39.58 %) |
EPS: | KRW137.79 |
FY | 2021 |
Ingresos: | KRW50.89B |
Beneficio Bruto: | KRW23.46B (46.09 %) |
EPS: | KRW158.70 |
Financial Reports:
No articles found.
Pharmicell Co., Ltd.
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to enhance the ejection fraction in patients with acute myocardial infarction reperfused by coronary angioplasty. The company's products under development include Cellgram_LC, a liver disease drug; Cellgram_ED for treating impotence; and Cellgram_DC, a cancer drug, as well as Hearticellgram_AM, a cardiac disease drug. It also develops and produces intermediates of raw material medicines, such as nucleosides, mPEGs, HDP-tosylate, and vincelactam; and low dielectric constant material, eco-friendly flame retardant, polyol synthesis catalyst, PET catalyst, etc. In addition, the company operates Twelve, a stem cell bank; develops and sells stem cell culture media cosmetics. Pharmicell Co., Ltd. was founded in 2002 and is headquartered in Seoul, South Korea.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico